In the not-too distant future, you may be able to go to a doctor's office, get tested for HIV/SARS CoV - 2 and walk out with pills or a prescription if you end up positive for the virus.
Finally, we have another potential tool: Dr. Joe Biden, Chief Medical Advisor to President Anthony Fauci, said Oct 6 at a White House briefing, a new oral drug that people can take soon after COVID -19 at home to reduce the risk of severe outcomes. The drug is Molnupiravir which was indicated by Ridgeback Therapeutics and Merck Co. Inc. MRK cuts the risk of hospitalization and death by 50%. It is currently under review at the Food and Drug Administration, and if approved, it will be the first oral antiviral to treat COVID- 19 patients in the U.S.
At least three other oral COVID - 19 pills are expected to have clinical data by Atea Pharmaceuticals Inc. APLIF and Roche Holding AG ROG, Fujifilm Holdings Corp. JP: 4901 via a group of drug makers including Appili Therapeutics Inc. AVIR and Dr. Reddy s Laboratories Ltd. RDY and Pfizer Inc. PFE, Shionogi Co. Ltd. 4507 also has an oral antiviral in a late stage
Coronavirus disease will be with us in the foreseeable future, even if it goes endemic, said Dr. Carl Dieffenbach, director of the division of AIDS for the National Institute of Allergy and Infectious Diseases and the official behind the government s $3.2 billion COVID-19 program. These pills could be incredibly valuable about keeping the brushfire beaten down. It makes sense that pharmaceutical companies are trying to figure out how antivirals can reduce the risk of someone dying or ending up with organ damage and an expensive hospital stay.
They are also evaluating whether these pills can reduce viral load or how long someone is infectious or sick — or even prevent people from end up with long COVID.
Using more antibiotics than usual for viral load testing can reduce the risk of long symptoms and potentially severe COVID symptoms in that individual themselves and also reduce the risk of spreading the virus to others, said Dr. Carolyn Bramante, a pediatrician from the University of Minnesota Medical School, who is leading a clinical trial testing repurposed drugs like ivermectin and metformin as COVID - 19 treatments.
If molnupiravir and other antivirals are authorized or approved, it s going to matter how quickly they are prescribed, if it s best to prescribe them after someone is exposed to the virus or once they report symptoms, and whether patients should take multiple tablets in a single day.
The oral antivirals by virtue of how they work are best to take within five days early in the course of disease, certainly within the first five days, said Dr. Armand Balboni, CEO of Appili, working with Fujifilm to develop their COVID - 19 pill, favipiravir I would argue that probably three days is where we need to use it, almost exactly like we used Tamiflu. Tamiflu, Roche s flu drug, is needed for effective care or to treat post-exposure prophylaxis, that can be used as a treatment or post-exposure prescription.
Experts compare HIV or influenza to SARS-CoV - 2. Both are transmittedable viruses that are best treated when someone who is infected gets access to medical care quickly. How these viruses respond to antiviral treatments can provide insight into several factors, including when to expect virus resistance to therapies and how quickly treatment needs to begin with COVID - 19 patients.
The goal is to get to a place where people who are diagnosed with coronavirus disease would start the medication as soon as possible after they are diagnosed, Dieffenbach said. If it is set up in a systemically correct way, you can either leave either with pills or a prescription for the medication at the time you test. In HIV, we can call that test and treat. But that may be difficult for the already disconnected health care system in the U.S. Making sure that people get tested immediately after possible exposure to COVID - 19 is one challenge. Could having a person follow through with getting a prescription and taking several pills per day be another obstacle?
Patients in the Fujifilm trial took four pills twice a day for five days, for example, while Merck s favipiravir is testing 90 tablets in 10 days. Pfizer s experimental antiviral requires two pills over 5 days for 2 days per day.
That said, the only treatments available for people with severe COVID-19 cases are monoclonal antibodies, which must be administered in a doctor's office and are intended only to those at risk of mild disease.
Sie get an infusion, Dieffenbach said. It's not a trivial thing. Because the monoclonal antibodies have not always been easy to get, that has hindered their use, especially among people living in rural America who live dozens or even hundreds of miles from the nearest hospital or clinic.
We need this because we need a toolbox, Balboni said. The toolbox contains vaccines in absolute detail. Nevertheless, it also includes monoclonal antibodies. It includes broad-spectrum oral antivirals and probably stacking the broad-spectrum oral antivirals to ensure that we don t develop resistance Read more of MarketWatch's coverage of CoVID 19 Antiviral drugs:
This development has almost entirely replaced global economy — and the stock market has ignored it mostly.
It is not a magic pill What Merck's antiviral drug could mean for vaccine hesitancy?